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Recent findings indicate that glucose uptake by contra~~g hind~mb [Acta Physiol. &and. (1982) 116, 
215-2221 and heart [Biochem. Biophys. Res. Commun. (1982) 108, 124-131) of the rat is stimulated by 
epinephrine acting through cr-adrenergic mechanisms. Since in exercise hepatic glucose output may be 
increased markedly by activation of cr-adrenergic receptors and matched by the increase in muscle glucose 
uptake (maintaining blood glucose levels relatively constant), it is now proposed that a general co- 
ordination of glucose metabolism may operate via or-adrenergic receptor mechanisms. The basis for this 
proposal is discussed. 
GIycoIysis Glucose uptake, output (Mu&e) (Liver) Exercise Catecholamine 
Alpha-receptor 
1. EXERCISE AND GLUCOSE 
METABOLISM 
Liver and muscle glycogen contribute 
significantly to the fuei homeostasis of the body. 
Liver glycogen is the primary source of blood 
glucose and hepatic glycogenolysis may be rapidly 
activated in response to exercise [3-51. Muscle 
glycogen is used for energy production for the 
muscle fibres in which it is contained. Thus its con- 
tribution to glucose homeostasis is indirect: (i) by 
supplementing the use of blood glucose; and (ii) by 
providing gluconeogenic precursors for hepatic 
glucose synthesis. 
Resting muscle takes up only a small amount of 
glucose [6,7]. Energy metabolism appears to be 
largely dependent upon free-fatty acid 
metabolism, as indicated by measurements of the 
local respiratory exchange and by direct deter- 
minations of free fatty acid and oxygen uptake 
[6-S]. 
Exercise gives rise to time- and work-intensity- 
dependent changes in fuel metabolism. For the 
human an initial net release of glucose by the exer- 
cising muscle [7] is followed by a large release of 
lactate 171. As work continues glucose uptake in- 
creases progressively and the release of lactate sub- 
sides. For the exercising forearm net glucose up- 
take may be 15 times the basal value after 10 min 
and as much as 35 times after 60 min [3,7]. At 
10 min the oxygen uptake appears to be used main- 
ly for carbohydrate oxidation [7]. If exercise con- 
tinues more than half of the oxidative metabolism 
is directed towards the oxidation of glucose taken 
up from the blood 171. For the rat in vivo it appears 
that exercise and epinephrine act in concert to 
balance increased hepatic glucose output with in- 
creased glucose uptake by muscle ES]. Recent 
detailed studies using the perfused rat hind-quarter 
have now clarified this situation further. In this 
system, contractions by themselves were found to 
briefly increase glycogenolytic activity [lo]. 
Physiological levels of epinephrine prolonged 
glycogen breakdown and increased the uptake of 
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glucose and oxygen [lo]. 
Blood flow changes during exercise favour in- 
creased oxygen (e.g., see review [ll]) and fuel 
supply to the working muscle and the blood con- 
centration of epinephrine increases [ 12- 141. 
However, despite the increased uptake of blood 
glucose it is clear that the hormonal response to ex- 
ercise is characterized by a fall in plasma insulin 
and a rise in plasma glucagon [3,15,16]. The 
decrease in insulin concentration during heavy ex- 
ercise is noteworthy since hypoinsulinaemia then 
occurs in spite of a moderate rise in the blood 
glucose level [3,17]. This trend suggests an inhibi- 
tion of insulin secretion [ 18,191 that may be 
mediated by ol-adrenergic receptors [20,21]. Never- 
theless a permissive effect of insulin on exercise- 
induced glucose uptake is suggested, as in the 
absence of this hormone, glucose uptake fails to 
increase in response to contraction [22]. 
The rise in plasma glucagon levels during exer- 
cise [3] may be attributable to catecholamine ac- 
tivation of the &adrenergic receptors of the A cells 
of the pancreas [23]. Since the rise in plasma 
glucagon appears to be slower to develop [3,15] 
than the increase in catecholamines [ 13,141, it may 
contribute less to the increase in hepatic 
glycogenolysis and more to the increase in gluco- 
neogenesis that occurs later and during recovery. 
From known responses in other tissues it could be 
predicted that the effects of glucagon on skeletal 
and heart muscle glucose metabolism would be 
similar to the @agonists. However, glucagon is 
considered to have no effect on skeletal muscle 
metabolism (e.g., see review [24]). 
The net effect of the above tissue-specific 
changes in glucose production and utilization is 
that the blood glucose concentration changes only 
marginally during moderate exercise [3,17,24]. 
3. (r-ADRENERGIC CONTROL OF HEART 
AND SKELETAL MUSCLE GLYCOLYSIS 
The increased glucose uptake by muscle in exer- 
cise is largely accounted for in terms of increased 
glycolysis. The increase in glycogenolysis also re- 
quires that carbon flux is accelerated through the 
reactions of glycolysis after glucose 6-phosphate. 
The rate controlling steps in muscle glycolysis 
have been examined in detail by numerous workers 
(e.g., see review [25] and references therein). 
2 
Glucose transport, glucose phosphorylation, 
phosphofructokinase and triose phosphate 
dehydrogenase have each been implicated in the 
regulation of this pathway. For heart it has been 
shown that glucose transport is increased by in- 
sulin, work-load and anoxia [26] as well as by (Y- 
adrenergic agonists [27]. The properties of muscle 
hexokinase are such that regulation is probably 
achieved by the intracellular concentration of ef- 
fectors (e.g., see review [26]); glucose 6-phosphate 
may have the most functional importance. Activa- 
tion of phosphofructokinase in heart has been 
shown in this laboratory to be mediated 
predominantly by an ar-adrenergic receptor 
mechanism [28]. Effecters of the enzyme do not 
appear to be involved and activation occurs via a 
Ca’+-dependent mechanism which is independent 
of /3-adrenergic receptor-mediated changes in 
cyclic AMP concentration and protein 
phosphorylation [28,29]. The activation of 
phosphofructokinase appears to result from in- 
creased affinity for the substrate fructose 
6-phosphate and decreased sensitivity to the in- 
hibitors, ATP and citrate (affording regulatory ad- 
vantage to the enzyme only when hexose 
6-phosphate concentrations are low and ap- 
proaching the Km). In addition, evidence for a key 
role of phosphofructokinase in the adrenergic on- 
trol of cardiac glycolysis was obtained; the activity 
ratio of the enzyme correlated well with the rate of 
glucose uptake over a wide range of concentrations 
of epinephrine [2]. /3-Adrenergic receptor- 
mediated activation of phosphofructokinase may 
occur at high concentrations of epinephrine coinci- 
dent with the activation of phosphorylase [29]. 
From our own observations it seems reasonable to 
predict that a similar dose relationship exists bet- 
ween CX- and fl-adrenergic receptors for the control 
of glucose uptake in heart. 
Epinephrine-mediated activation of skeletal 
muscle phosphofructokinase has also been 
reported [30] but the nature of the adrenergic 
mechanism involved was not characterized. 
Glucose and non-metabolizable monosaccharide 
uptake by resting non-cardiac muscle has been 
studied by several groups. Both inhibitory and 
stimulatory effects of epinephrine have been 
reported. Walaas and Walaas [31] showed in early 
studies that epinephrine could decrease glucose up- 
take in rat diaphragm. Further examination of this 
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phenomenon in rat diaphragm revealed that both 
inhibition [32-351 and no effect [33,35] could be 
demonstrated epending on the ionic composition 
of the incubation media [33,35]. Newsholme and 
Randle [36] reported that 66 PM epinephrine in- 
creased the uptake of D-3-0-methylglucose, but 
not D-xylose in diaphragm. In 1978, Bihler and 
colleagues [37,38] reported that 10 nM-10 PM 
epinephrine inhibited the transport of 3-0- 
methylglucose in rat diaphragm and soleus. 
However, at very high concentrations (0.1-l mM) 
transport was stimulated in diaphragm [37]. Both 
the inhibitory and stimulatory effects of 
catecholamines on 3-O-methylglucose transport 
were mediated by P-adrenergic receptors [37,38]. 
Saitoh et al. [39] reported an increase in glucose 
utilization and 3-0-methylglucose uptake by 
diaphragm which were each mediated by CY- 
adrenergic receptors. 
In an attempt to resolve these apparently con- 
flicting data, the perfused hindquarter system has 
been used. Chiasson et al. [40] showed that 0.1 PM 
epinephrine increased basal glucose uptake and 
decreased glucose uptake when the latter was max- 
imally stimulated by insulin (1 mU/ml). Chiasson 
et al. [40] ascribed both the stimulatory and in- 
hibitory effects of epinephrine to fi-adrenergic 
receptors, although a partial inhibition of 
epinephrine-stimulated glucose uptake was noted 
with the a-blocker. Epinephrine increased the free 
intracellular 2-deoxyglucose space but did not in- 
crease the uptake of 3-0-methylglucose by muscle 
of the perfused rat hindlimbs. In view of the obser- 
vations that epinephrine can increase the uptake of 
3-0-methylglucose into isolated rat adipocytes by a 
&adrenergic receptor mechanism, Chiasson et al. 
argued that their observed stimulatory effects on 
glucose uptake by the hindlimb were due to effects 
on adipose tissue [40]. The inhibitory effect of 
epinephrine on muscle glucose uptake [40] was 
considered to be consistent with earlier explana- 
tions; i.e., that it resulted from inhibition of the 
hexokinase reaction due to the large rise in glucose 
6-phosphate and fructose 6-phosphate induced by 
glycogenolysis (a &receptor-mediated process 
[411). 
More recently, another group [l] have also ap- 
plied the perfused hindquarter in an attempt to 
resolve these issues. Richter et al. [l] observed that 
at rest 2.4 x lo-’ M epinephrine significantly in- 
creased oxygen uptake, glucose uptake, lactate 
release and perfusion pressure of the perfused 
hindquarter. Phentolamine blocked the epine- 
phrine-mediated increases in oxygen uptake, 
glucose uptake and perfusion pressure (the latter 
being decreased to less than control). Propranolol 
+ epinephrine (which together accentuate the (Y- 
agonist activity of epinephrine) further increased 
glucose uptake over epinephrine used alone. Lac- 
tate release was decreased to less than epinephrine 
alone but remained higher than control (possibly 
suggesting an cr-adrenergic receptor-mediated in- 
crease in lactate oxidation). Electrical stimulation 
increased all four parameters [l] and did not 
diminish the significant effect of epinephrine on 
glucose uptake [lo]. The combination of epine- 
phrine + propranolol retained highly significant 
stimulatory effects on glucose uptake, oxygen up- 
take and perfusion pressure [l]. 
It is not clear why such differing results have 
been obtained by the two groups ([l,lO] and [40]) 
using the same technique of hindlimb perfusion. 
However, important differences in approach may 
have been relevant. Chiasson et al. [40] used the 
system at rest for all their studies and perfused in 
a non-recirculating manner during the experimen- 
tal period. This group. also used medium contain- 
ing 10 mM glucose. Richter et al. [l,lO] examined 
the effects of epinephrine at rest and during elec- 
trical stimulation. A recirculating mode was used 
and a physiological evel of insulin (75 &J/ml) was 
present throughout all experiments [l, lo]. This 
group used medium containing 6 mM glucose 
[1,101. 
The observations made by Richter et al. (11 are 
consistent with our own findings for the Langen- 
dorff perfused beating rat heart, from which we 
have made speculations regarding mechanisms in 
skeletal muscle (e.g., see [29]). The studies with 
perfused hearts lead us to believe that the 
magnitude and duration of the P-adrenergic- 
mediated increase in the intracellular concentra- 
tion of glucose 6-phosphate in non-contracting 
muscle is essentially non-physiological. Instead of 
a transient increase in concentration due to 
epinephrine (perhaps lasting only 3-5 min as in 
contracting heart [29]) the concentration of 
glucose 6-phosphate can remain elevated for 
30 min or more in muscle at rest (e.g., [40]). Con- 
tracting muscle requires energy from metabolism 
3 
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and thus accounts for the more rapid turnover of 
glucose 6-phosphate when compared with the 
resting state. Contracting muscle also affords the 
appropriate physiological environment for the ino- 
tropic effects of epinephrine to develop [l]. We 
have proposed that the positive inotropy, increase 
in glucose uptake and activation of phospho- 
fructokinase in rat heart are mediated in a co- 
ordinated manner by an ar-adrenergic receptor 
mechanism [42]. From the data of Richter et al. [l] 
it seems reasonable to propose that the same rela- 
tionships may occur in skeletal muscle. 
4. (r-ADRENERGIC CONTROL OF HEPATIC 
GLUCOSE OUTPUT AND GLUCONEO- 
GENESIS 
There is now considerable evidence that 
catecholamines rapidly activate both hepatic 
glycogenolysis and gluconeogenesis in the rat 
through an ar-adrenergic receptor mechanism that 
is independent of changes in the intracellular level 
of cyclic AMP (e.g., see [43] and references 
therein). The stimulation of carbohydrate 
metabolism by catecholamines is smaller in 
magnitude than that caused by glucagon or cyclic 
nucleotides [44-461 and is inhibited by o-blockers, 
but not by /3-blockers [46,47]. Although it is 
regarded that catecholamines stimulate glyco- 
genolysis by increasing the cytosolic concentration 
of Ca2+ and activating phosphorylase kinase 
[48-501, the mechanism by which o-receptor 
stimulation leads to increased gluconeogenesis i  
still controversial. Effects of epinephrine at 
pyruvate kinase-phosphoenol pyruvate carboxy- 
kinase and at phosphofructokinase-fructose 
1 ,dbisphosphatase have been claimed (e.g., 
reviews [51,52] and references therein). Hormone- 
mediated changes in concentration of the key 
regulator fructose 2,6-bisphosphate may have an 
important role to play in the cr-adrenergic ontrol 
of hepatic gluconeogenesis 153,541. 
5. THE PROPOSED CO-ORDINATION OF 
MUSCLE AND HEPATIC GLUCOSE 
METABOLISM IN EXERCISE 
Fig.1 outlines this proposal. The essential com- 
ponents are: 
ii> 
(ii) 
Exercise in the mammal leads to increased 
sympathetic nervous system activity 
(norepinephrine) and release of adrenal 
medullary hormones (epinephrine and 
norepinephrine). 
Post-synaptic adrenergic receptors in heart, 
pancreas, liver and skeletal muscle are 
activated. 
A catecholamines 
to increase glycolysis 
and heart force 
increase gluconeogenesis from lactate 
and glucogenic amino acids; ) 
- lactate, amino acids 
Fig.1. The co-ordination of muscle and hepatic glucose metabolism in exercise: a role for cy-adrenergic receptors. 
4 
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(iii) In heart, a-adrenergic receptor mechanisms 
act to increase glucose transport, the activity 
ratio of phosphofructokinase and force of 
contraction. Increased oxidation of lactate 
may also occur. If high levels of epinephrine 
are attained, P-receptor mechanisms act to 
stimulate glycogenolysis. 
In pancreas, ar-receptor mechanisms act to 
suppress insulin release. 
In liver, cr-receptor mechanisms act to increase 
glucose output into the blood from glycogen 
and to increase gluconeogenesis. 
In contracting skeletal muscle, o-receptor 
mechanisms act to increase glucose uptake and 
its ut~ization by reactions of glycolysis. In- 
otropy and oxygen uptake are also increased. 
@-Receptor mechanisms act to increase 
glycogenolysis. 
6. QUESTIONS ~MAINING 
(1) The hypothesis proposed here would appear 
to be largely inconsistent with the observed effects 
of administering epinephrine in vivo. It is clear 
from studies of this latter kind that epinephrine ad- 
ministration gives rise to a decrease in glucose 
clearance [55-601. However, in each of these 
studies non-exercising animal or human subjects 
were used. Under these conditions requirements 
for energy from glucose metabolism are minimal in 
muscle and events similar to adding epinephrine to 
non-contracting muscle preparations in vitro occur 
(see above). Thus a /3-adrenergic receptor- 
mediated increase in muscle glycogenolysis may be 
the predominant biochemical response. Diminish- 
ed peripheral uptake of glucose, together with 
hyperglycemia and a decreased hepatic glucose 
output, results [60]. In the few studies where 
epinep~ne has been injected into exercising 
animals (e.g., [9]) the increased glucose uptake by 
contracting muscle has been viewed as the con- 
tributing factor in lowering blood glucose [9]. Fur- 
ther studies of this latter kind will help resolve the 
issue. 
(2) This present proposal is largely based on 
observations made in rat tissues. The situation is 
less clear in other species. Exton [43] has argued 
that data support a role for cr-receptors in 
cat~hol~ine actions in hyperglycemia or hepatic 
glycogenolysis in mouse, cat, rabbit and guinea 
pig, but that the importance of at-receptors relative 
to &receptors is uncertain. Data supporting the 
predo~~t role for P-receptor in the dog are 
questioned and the data indicating a role for cy- 
receptors in man are considered to be incomplete 
t431. 
(3) The question of t~get-tissue a-receptors in 
muscle requires thorough examination. For heart, 
sub-type characterization of the adrenergic recep- 
tors indicates that they are (~1 [61], However, the 
membrane preparations used for sub-typing 
studies have not as yet been shown to be 
homogeneous prep~ations of sarcolemma from 
ventricular muscle cells. Thus the possibility re- 
mains that ar-adrenergic effects on heart result in- 
directly from the vasoconstriction initiated by 
cul-receptors in vascular smooth muscle cells. 
Similar reasoning could apply to skeletal muscle. 
As yet there has been no report of a-receptors on 
skeletal muscle sarcolemma. 
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